Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.”In the company’s words, NCT02462603 on ClinicalTrials.gov
- Tested for
- Parkinson's Disease
- Main trialPhase 2
- “Open-label study with 30-day run-in phase and adaptive design component to include more participants if deemed appropriate by investigators.”In the company’s words, NCT02462603 on ClinicalTrials.gov
Other drugs for Parkinson's Disease
- PembrolizumabMerck & Co. · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
- LenvatinibEisai · Merck & Co. · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- BHV-8000Biohaven · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 8 Jan 2019 | Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026